Home
Free App Analytics
NbN3
NbN3 Vs. Maudsley Prescribing Guideline

NbN3 vs Maudsley Prescribing Guideline Usage & Stats

It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients. This practice is confusing. • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature. • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. • In this second edition 22 new medications were added so NbN includes now 130 medications. This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth. The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known. Therefore this nomenclature is based on: 1. The need to treat now. 2. Updated neuroscience insights. 3. The judgment of the members of the taskforce. Along these lines, we have come up with the following proposal: The Nomenclature: Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action. We also added 4 additional dimensions 4 Additional Dimensions: Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve" Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour. As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.

Apple App Store
Free
Medical

Store Rank

- -

Maudsley Prescribing Guideline

"Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content. The revised 14th edition of the essential reference for the prescribing of drugs for patients with mental health disorders. Provides succinct coverage of drug treatment of psychiatric conditions and formulating prescribing policy in mental health. The new edition of the world-renowned reference guide on the use of medications for patients presenting with mental health problems? The Maudsley Prescribing Guidelines in Psychiatry is the essential evidence-based handbook on the safe & effective prescribing of psychotropic agents. Covering both common & complex prescribing situations encountered in day-to-day clinical practice, this comprehensive resource provides expert guidance on drug choice, minimum & maximum doses, adverse effects, switching medications, prescribing for special patient groups & more. Each clear & concise chapter includes an up-to-date reference list providing easy access to the evidence on which the guidance is based. The 14th edition has been fully updated to incorporate the latest available research, the most recent psychotropic drug introductions & all psychotropic drugs currently used in the UK, USA, Canada, Australia, New Zealand & Japan. Several new sections cover topics such as deprescribing of major psychiatric drugs, prescribing psychotropics at the end of life, the treatment of agitated delirium, the genetics of clozapine prescribing, the use of weekly penfluridol, and the treatment of psychotropic withdrawal. Featuring contributions by an experienced team of psychiatrists and specialist pharmacists, the new edition of The Maudsley Prescribing Guidelines in Psychiatry: * Provides succinct coverage of drug treatment of psychiatric conditions & formulating prescribing policy in mental health * Covers a wide range of psychiatric conditions including schizophrenia, bipolar disorder, depression & anxiety, borderline personality, eating disorders & many others * Provides advice on prescribing for children & adolescents, older people, pregnant women & other special patient groups * Offers new sections on genetic prescribing, long-acting injectable formulations, ketamine administration and uses & dopamine super-sensitivity * Includes referenced information on off-label prescribing, potential interactions with other substances such as alcohol, tobacco & caffeine, and treating patients with comorbid physical conditions * Whether in the doctor's office, in the clinic, or on the ward, The Maudsley Prescribing Guidelines in Psychiatry, 14th Edition is a must-have for psychiatrists, pharmacists, neuropharmacologists, clinical psychologists, nurses & other healthcare professionals working in mental health, as well as trainees and students in medicine, pharmacy & nursing. Content licensed from printed edition ISBN 10:1119772222 & ISBN 13:9781119772224 SUBSCRIPTION: Please purchase a yearly auto-renewing subscription to receive content access & available updates. Yearly auto-renewing payments- $42.99 Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable. If you have any questions or comments, email us any time: customersupport@skyscape.com or call 508-299-3000 Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx Author(s): David M. Taylor, Thomas R. E. Barnes, Allan H. Young Publisher: John Wiley & Son Inc. and its affiliates